Hanmi and HHP will grant Gilead an exclusive license to Encequidar and provide access to drug supply. SEOUL, South Korea, Sept. 29, 2025 /PRNewswire/ -- Hanmi Pharm announced on September 29 that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc....
Hence then, the article about hanmi s oral delivery platform compound licensed to gilead was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Hanmi's Oral Delivery Platform Compound Licensed to Gilead )
Also on site :
- What ‘Legend of Zelda’ Superfan Jon Batiste Thinks of ‘Ocarina of Time’ Remake and the Game’s Iconic Score
- Panera’s New Limited-Edition Holiday Collectible Cup Is Guaranteed To Fly Off Shelves—How To Secure Yours
- Run, Don’t Walk: These 11 Trader Joe’s November Freezer Drops Are Already Flying Off Shelves